Demonstrations indicated that these newly designed Arf1 inhibitors exhibit low toxicity and robust anti‐tumor activities in various mouse tumor models, including liver, colon, breast, and melanoma, as well as PDX tumor models. This evidence concerns the gene ARF1 and neoplasm.